Furukawa Kenei, Shiba Hiroaki, Horiuchi Takashi, Shirai Yoshihiro, Haruki Koichiro, Fujiwara Yuki, Sakamoto Taro, Gocho Takeshi, Yanaga Katsuhiko
Department of Surgery, Jikei University School of Medicine 3-25-8 Nishi-Shinbashi, Minato-ku, Tokyo, 105-8461, Japan.
J Hepatobiliary Pancreat Sci. 2017 Apr;24(4):199-205. doi: 10.1002/jhbp.436. Epub 2017 Mar 12.
The Barcelona Clinic Liver Cancer (BCLC) classification is the most widely used staging system for hepatocellular carcinoma (HCC), but its prognostic ability in patients after resection has not been yet validated. The aim of this study was to evaluate the BCLC classification among patients after resection.
The subjects were 196 patients who underwent hepatic resection for HCC between April 2003 and December 2014 at Jikei University Hospital. All patients were classified into a tumor stage according to the BCLC classification. Overall survival rate was calculated according to stages defined by the BCLC classification.
Overall survival rates at 1, 3 and 5-year were 100%, 95.2% and 95.2% in BCLC 0, 96.7%, 90.0% and 78.4% in BCLC A solitary, 86.2%, 86.2% and 86.2% in BCLC A multiple, 100.0%, 78.8% and 78.8% in BCLC B and 86.5%, 63.3% and 57.6% in BCLC C, respectively. Postoperative complications and mortality rates in relation to BCLC stage were comparable.
The BCLC treatment algorithm should consider the role of resection also for multiple early, intermediate and advanced stages.
巴塞罗那临床肝癌（BCLC）分期系统是肝细胞癌（HCC）最广泛使用的分期系统，但其在切除术后患者中的预后能力尚未得到验证。本研究的目的是评估BCLC分期系统在切除术后患者中的应用。
研究对象为2003年4月至2014年12月在慈惠会医科大学医院接受肝癌肝切除术的196例患者。所有患者均根据BCLC分期系统进行肿瘤分期。根据BCLC分期系统定义的分期计算总生存率。
BCLC 0期患者1年、3年和5年总生存率分别为100%、95.2%和95.2%；BCLC A期单发患者分别为96.7%、90.0%和78.4%；BCLC A期多发患者分别为86.2%、86.2%和86.2%；BCLC B期患者分别为100.0%、78.8%和78.8%；BCLC C期患者分别为86.5%、63.3%和57.6%。与BCLC分期相关的术后并发症和死亡率相当。
BCLC治疗方案应考虑切除在多个早期、中期和晚期阶段的作用。
